|
Orthologous residues
|
|
TORC2 (human): S171‑p, TORC2 (mouse): S171‑p, TORC2 (rat): S171‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), hepatocyte-liver, HepG2 (hepatic)
|
|
Cellular systems studied:
cell lines, primary cultured cells
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
QIK (mouse)
|
siRNA inhibition of enzyme, activation of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
meal feeding
|
|
|
|
increase
|
|
|
fasting
|
|
|
|
decrease
|
|
|
refeeding
|
|
|
|
increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
insulin, forskolin
|
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, inhibited, intracellular localization, protein degradation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
COP1 (mouse)
|
|
Not reported
|
|
|
co-immunoprecipitation
|
|
|
Comments:
phosphorylation of this site stimulated by meal feeding or insulin alone leads to TORC2 cytoplasmic translocation and its ubiquitin-based degradation;
|
